CPhI Worldwide to return in 2021

CPhI Worldwide 2021 31 August - 2 September 2021, Milan, Italy.
CPhI Worldwide will be held next year in Milan (Fiera Milano) for the first time in over a decade - following its postponement in 2020. The event returns at an apt moment, as the pharma industry in Italy is anticipated to be one of the main beneficiaries of geo-diverse sourcing strategies.

Italy is Europe's largest producer and exporter of APIs - 85% are exported to North America, the EU and Japan[1] - and the 2020 CPhI Annual Report Survey indicates the country is well set for growth in 2021, as pharma looks for new manufacturing partners. The results show that Italy has improved its 'growth ranking' by 16% in a year - the largest rise of any country - with Western European API manufacturers predicted to be the 'biggest beneficiaries of supply chain changes' by some 47% of respondents.

To further empower the industry's growth, CPhI Worldwide 2021 will implement a 'hybrid event model', featuring onsite exhibition and conference agenda, as well as online sessions and matchmaking. Offering further encouragement for the prospects of attendees, nearly two thirds (61%) of the industry foresees an improved 'business outlook for pharma' in 2021, with 67% 'actively looking for new partners'.

"We are really excited to be hosting the 2021 event in Milan - Europe's largest pharma manufacturing region - especially with Italy seeing the largest reputational and growth increases of any country in our recent executive survey. Pharma manufacturers here, and particularly ingredients producers, are widely expected to see sizable growth rates in 2021, with companies now actively looking to make new contacts, and implement multi-partner sourcing strategies. That’s why meeting new contacts at the event next year will be so important, as it will be the first time the global community has come back together," commented Orhan Caglayan, Brand Director at CPhI Worldwide/Informa.

CPhI Worldwide 2021 in Milan will feature all five co-located events; including P-MEC, FDF, ICSE, BioProduction and Innopack, with Informa's AllSecure Standards implemented - providing the most robust at-event biosafety measures, spanning dozens of special health&safety protocols.

Caglayan added: "CPhI Worldwide is international pharma’s only true one-stop-hub for everything from equipment, generics and packaging through to biologics, ingredients and contract services. We believe that quality of life can be improved through attainable healthcare, delivered by more accessible and affordable medicines. It is why over the last 30+ years we have built a platform to unite the specialist communities improving healthcare - and our role has never been more important as new supply chain partnerships are sought globally. We help accelerate pharma advancement by enabling attendees to meet with not just one or two, but hundreds of potential partners simultaneously. Nowhere else can you do this as well as at CPhI Worldwide and we cannot wait to welcome global pharma to Milan."

For further information, please visit:
https://www.cphi.com/europe/en/home.html

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; Finished Dosage Formulation for every aspect of the finished dosage supply chain; and NEX for natural extract products, applications and solutions.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

The Informa Markets annual schedule of Pharmaceutical events include: CPhI & P-MEC China 2020 (16-18 December 2020 (Virtual)); CPhI & P-MEC India 2020 (28-29 January 2021 at the India Expo Mart, Greater Noida, Delhi NCR - Delhi, India); CPhI Japan (14-16 April, 2021 at the Big Sight Exhibition Centre - Tokyo, Japan); Pharmapack Europe 2021 (19-20 May, 2021 at the Paris Expo, Porte de Versailles - Paris, France); CPhI and P-MEC China 2021 (22-24 June, 2021 at SNIEC - Shanghai, China); CPhI South East Asia (4-6 August, 2021 at Challenger 2, IMPACT, Muang Thong Thani, Thailand); CPhI North America (10 August - 12 August, 2021 at Pennsylvania Convention Centre - Philadelphia, USA); CPhI Korea (11-13 August 2021), COEX - Seoul, Korea).CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (31 August - 2 September 2021 at Fiera Milano, Milan); CPhI Middle East & Africa (26-28 September, 2021 at the Riyadh International Convention & Exhibition Center, Riyadh, Saudi Arabia).

1. Italian Pharma Outlook, Tuesday 6th October at the CPhI Festival of Pharma

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...